Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386511 | 1.00 | ADORA3 (0.41) | ADORA3HSD17B10MAPK8MAPK10CHRNB2 | |
| SCHEMBL5909567 | 0.83 | CHRNB2 (0.50) | HSD17B10CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL103880 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL30714958 | 0.81 | — | — | |
| SCHEMBL17506514 | 0.81 | CHRNB2 (0.38) | HSD17B10CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL15387078 | 0.81 | CHRNB2 (0.38) | HSD17B10CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL30622698 | 0.81 | ADORA3 (0.40) | ADORA3HSD17B10MAPK8MAPK10OPRM1 | |
| SCHEMBL24920450 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL20300465 | 0.80 | TP53 (0.46) | HSD17B10CHRNB2CHRNA4CHRNA7CHRNB4 | |
| SCHEMBL18367816 | 0.80 | TP53 (0.46) | HSD17B10CHRNB2CHRNA4CHRNA7CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116916924-A | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-2397479-A1 | HETERO RING DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7629468-B2 | Neuroprotectants, analgesics or anticonvulsants | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| US-7517517-B2 | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-14 | — | — | US | disclosed |
| WO-2003082350-A2 | RADIOLABELLED QUINOLINE AND QUINOLINONE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | ADORA3 1060/4885HSD17B10 2557/4885MAPK8 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.